Cargando…

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study

BACKGROUND: Circulating tumour cells (CTC) in the blood have been accepted as a prognostic marker in patients with metastatic colorectal cancer (CRC). Only limited data exist on the prognostic impact of CTC in patients with early stage CRC using standardised detection assays. The aim of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bork, U, Rahbari, N N, Schölch, S, Reissfelder, C, Kahlert, C, Büchler, M W, Weitz, J, Koch, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402459/ https://www.ncbi.nlm.nih.gov/pubmed/25867263 http://dx.doi.org/10.1038/bjc.2015.88

Ejemplares similares

Prognostic value of circulating endothelial cells in metastatic colorectal cancer
por: Rahbari, Nuh N, et al.
Publicado: (2017)

Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer
por: Schölch, Sebastian, et al.
Publicado: (2019)

Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer
por: Schölch, Sebastian, et al.
Publicado: (2016)

Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection
por: Yang, Cui, et al.
Publicado: (2017)

Influence of two different resection techniques (conventional liver resection versus anterior approach) of liver metastases from colorectal cancer on hematogenous tumor cell dissemination – prospective randomized multicenter trial
por: Schmidt, T, et al.
Publicado: (2008)

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)

LDB1 overexpression is a negative prognostic factor in colorectal cancer
por: García, Sebastián A., et al.
Publicado: (2016)

A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival
por: Pecqueux, Mathieu, et al.
Publicado: (2016)

A randomised controlled trial to evaluate and optimize the use of antiplatelet agents in the perioperative management in patients undergoing general and abdominal surgery- the APAP trial (ISRCTN45810007)
por: Antolovic, Dalibor, et al.
Publicado: (2011)

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy
por: Rahbari, Nuh N, et al.
Publicado: (2014)

A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer
por: Reissfelder, Christoph, et al.
Publicado: (2011)

Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
por: Lerbs, Tristan, et al.
Publicado: (2017)

Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
por: Rahbari, Nuh N, et al.
Publicado: (2011)

IVC CLAMP: infrahepatic inferior vena cava clamping during hepatectomy - a randomised controlled trial in an interdisciplinary setting
por: Rahbari, Nuh N, et al.
Publicado: (2009)

Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555)
por: Rahbari, Nuh N, et al.
Publicado: (2012)

Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies
por: Antolovic, Dalibor, et al.
Publicado: (2010)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Interrupted versus continuous suture technique for biliary-enteric anastomosis: randomized clinical trial
por: Seifert, Lena, et al.
Publicado: (2023)

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
por: Kahlert, C, et al.
Publicado: (2009)

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
por: Schölch, Sebastian, et al.
Publicado: (2014)

Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases
por: Volk, Andreas M., et al.
Publicado: (2016)

Circulating tumour cells in patients with lung cancer universally indicate poor prognosis
por: Jin, Fukang, et al.
Publicado: (2022)

Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review
por: Peach, G, et al.
Publicado: (2010)

AB0 blood group and prognosis in patients with pancreatic cancer
por: Rahbari, Nuh N, et al.
Publicado: (2012)

Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients
por: Haug, U, et al.
Publicado: (2007)

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer
por: Androulakis, N, et al.
Publicado: (2012)

Clamp-Crushing versus stapler hepatectomy for transection of the parenchyma in elective hepatic resection (CRUNSH) - A randomized controlled trial (NCT01049607)
por: Rahbari, Nuh N, et al.
Publicado: (2011)

Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer
por: Kahlert, Christoph, et al.
Publicado: (2014)

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
por: Hamaoka, T, et al.
Publicado: (2010)

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
por: Hansen, T F, et al.
Publicado: (2015)

Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
por: Damianovich, D, et al.
Publicado: (2007)

Differential Effects of Trp53 Alterations in Murine Colorectal Cancer
por: Betzler, Alexander M., et al.
Publicado: (2021)

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
por: Jonasch, E, et al.
Publicado: (2008)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2008)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer
por: van Wyk, Hester C, et al.
Publicado: (2016)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
por: Nwosu, A C, et al.
Publicado: (2008)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour
por: Pine, J K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fr7brkkpnipb3b6bcig3ud681u